Using 3D printing to create long-lasting treatments for bacterial vaginosis
3D-bioprinting of sustained- and phased-release antibiotic and probiotic scaffolds to treat bacterial vaginosis
This study is working on new 3D-printed products that can slowly release antibiotics and probiotics to help treat bacterial vaginosis (BV), making it easier for women to manage this common condition without needing to apply treatments as often.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11013934 on NIH RePORTER |
What this research studies
This research focuses on developing innovative 3D-printed scaffolds that can deliver antibiotics and probiotics in a sustained and phased manner to treat bacterial vaginosis (BV). BV is a common condition affecting many women, characterized by an imbalance in the vaginal microbiome. The project aims to improve treatment adherence and effectiveness by creating long-acting products that reduce the need for frequent applications. By utilizing advanced 3D printing technology and computational modeling, the researchers will test these prototypes in laboratory settings and eventually in clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are reproductive-age women who have been diagnosed with bacterial vaginosis.
Not a fit: Patients who do not have bacterial vaginosis or those with other unrelated vaginal health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide women with a more effective and convenient treatment option for bacterial vaginosis, reducing recurrence rates and improving overall vaginal health.
How similar studies have performed: While the approach of using 3D printing for medical treatments is innovative, similar strategies in delivering probiotics and antibiotics have shown promise in other contexts, indicating potential for success.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Frieboes, Hermann — University of Louisville
- Study coordinator: Frieboes, Hermann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.